Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

NCT07430306 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07430306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07430306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
April 13, 2026
Completion date
January 26, 2029
Enrollment
245 (estimated)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus